Itrabat 200mg Capsule contains Itraconazole, a broad-spectrum triazole antifungal agent used primarily for the treatment of various fungal infections. Itraconazole exerts its effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. Disruption of ergosterol synthesis leads to increased membrane permeability and ultimately fungal cell death. Itrabat 200mg is indicated for the management of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. The capsule formulation ensures adequate bioavailability and convenient oral administration. It is important to administer Itrabat with food to enhance absorption. Dosage and duration of therapy should be tailored based on the type and severity of infection, as well as patient-specific factors. Caution is advised in patients with hepatic impairment or congestive heart failure, and periodic monitoring of liver function tests is recommended during prolonged therapy. Potential drug interactions due to CYP3A4 inhibition necessitate careful review of concomitant medications. Common adverse effects include gastrointestinal disturbances, headache, and rash. Itrabat 200mg Capsule should be used under medical supervision to ensure safety and efficacy in antifungal treatment.